München (ots) – Daiichi Sankyo und The Medicines Company (Deutschland) GmbH arbeiten ab sofort in einer Vertriebskooperation zusammen. Zum 1. November 2011 wird die Daiichi Sankyo Deutschland GmbH den Vertrieb von Angiox® (Bivalirudin), einem Gerinnungshemmer der The Medicines Company, unterstützen. Angiox® (Bivalirudin) ist ein direkter Thrombininhibitor. Das Medikament ist bei Patienten mit akutem Koronarsyndrom (ACS) [...]
Tag Archive > Daiichi Sankyo
CMC Biologics gibt Vertragsabschluss mit Daiichi Sankyo zur Entwicklung und Herstellung von Antikörpern bekannt
Seattle und Kopenhagen, Dänemark (ots/PRNewswire) – CMC Biologics hat heute den Abschluss eines Vertrags mit Daiichi Sankyo Co., Ltd. (“Daiichi Sankyo”) zu einer dreijährigen Zusammenarbeit bei der Prozessentwicklung und Herstellung mehrerer Antikörper in der klinischen Phase bekanntgegeben. Die beiden Unternehmen haben vor kurzem mit der Arbeit an ihrem ersten gemeinsamen Projekt in der Produktionsanlage Bothell [...]
Daiichi Sankyo entscheidet sich für Veeva CRM, um die Kundenbindung in Grossbritannien zu verbessern
BARCELONA, Spanien, und GERRARDS CROSS, England, July 26, 2011 (ots/PRNewswire) — Führendes Pharmaunternehmen wird iRep bei britischen Teams einsetzen Veeva Systems gab heute bekannt, dass Daiichi Sankyo, eines der Top-20-Pharmaunternehmen der Welt, sein bisheriges standortgebundenes Customer Relationship Management (CRM)-System in Grossbritannien durch Veeva CRM ersetzt. Daiichi Sankyo wird Veeva CRM bei allen Vertriebsteams in Grossbritannien [...]
Daiichi Sankyo Europe wächst: Deutliche Fortschritte bei Onkologie, Stärkung der Kernkompetenz Kardiovaskular (mit Bild)
Bild: http://presseportal.de/bild/188043_thumb.w200_daiichi_sankyo_europe_gmbh.jpg Frankfurt (ots) – Daiichi Sankyo baut in Europa ein neues Geschäftsfeld Onkologie auf. Damit will der japanische Pharmakonzern neben seiner bisherigen Kernkompetenz bei Herz-Kreislaufmitteln auch den Eintritt in den Markt für Krebsmedikamente vorbereiten. “Wir verfügen in der Onkologie mittlerweile über eine gut gefüllte Pipeline an neuen, innovativen Arzneimittelkandidaten. Wir gehen davon aus, dass [...]
Daiichi Sankyo Receives First Market Approval in Japan for LIXIANA(R) (Edoxaban), a Direct Oral Factor Xa Inhibitor, for the Prevention of Venous Thromboembolism After Major Orthopedic Surgery
Tokyo (ots/PRNewswire) – Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo), announced today that the company has received its first marketing approval for LIXIANA(R) (JAN: Edoxaban Tosilate Hydrate, INN:edoxaban) 15 mg and 30 mg tablets, by the Ministry of Health, Labor and Welfare in Japan. Edoxaban, which is being developed solely by Daiichi Sankyo, is a [...]
Global Phase III Trial With Selective c-MET Inhibitor Tivantinib (ARQ 197) Starts Enrolling Patients in Europe
Munich (ots/PRNewswire) – Daiichi Sankyo announced today that it has begun enrolling patients in Europe into a large, multinational phase III trial of tivantinib (ARQ 197). Tivantinib is an investigational small molecule inhibitor of the c-MET receptor tyrosine kinase in final phase of clinical development for the treatment of advanced, non-squamous, non-small cell lung cancer [...]
Pieris and Daiichi Sankyo Sign Therapeutic Collaboration to Develop Anticalin(R) Therapeutics
Freising, Germany (ots) – Pieris AG announced today the signature of a collaboration and license agreement with Daiichi Sankyo Company Limited (hereinafter Daiichi Sankyo; headquartered in Chuo Ward, Tokyo, TSE 4568), under which Pieris will apply its proprietary Anticalin scaffold technology to discover novel Anticalins against two Daiichi Sankyo targets. Upon discovery and achievement by [...]
Daiichi Sankyo and ArQule Enroll First Non-Small Cell Lung Cancer Patient Into Global Phase III Trial for ARQ 197
Tokyo and Woburn, Massachusetts (ots/PRNewswire) – Daiichi Sankyo Company, Limited (TSE 4568) and ArQule, Inc. today announced that the first patient has been enrolled in the phase III trial of ARQ 197, an investigational selective inhibitor of the c-Met receptor tyrosine kinase, in combination with erlotinib, for patients diagnosed with non-squamous, non-small cell lung cancer [...]
Daiichi Sankyo Announces First European Approval for Sevikar HCT(R), a New Three-in-one Combination Product for the Treatment of High Blood Pressure*
Munich (ots/PRNewswire) – Daiichi Sankyo Europe announced today that Sevikar HCT(R) is now approved in Germany, the first market to launch this new once-daily three-in-one combination product for the treatment of high blood pressure (BP). This new drug combines the three widely prescribed blood pressure treatments – olmesartan medoxomil, amlodipine, and hydrochlorothiazide (HCT) – in [...]
Edoxaban Demonstrates Superior Efficacy Compared With Enoxaparin Sodium in Preventing VTE After Total Hip Replacement
Tokyo (ots/PRNewswire) – Daiichi Sankyo Company, Limited announced that its investigational once-daily oral, direct factor Xa inhibitor, edoxaban, was shown to be superior to enoxaparin sodium in preventing venous thromboembolic (VTE) events in patients following total hip replacement (THR), a type of major orthopedic surgery. Results from the Phase III STARS J-V (Studying Thrombosis After [...]
ArQule and Daiichi Sankyo Expand Drug Discovery Collaboration in Oncology
Woburn, Massachusetts (ots/PRNewswire) – ArQule, Inc. and Daiichi Sankyo Co., Ltd. (TSE 4568) today announced the expansion of their research, development and license agreement for the discovery of novel kinase inhibitors in the field of oncology. This expanded agreement establishes a third therapeutic target, with an option for a fourth, in the field of oncology, [...]
ArQule und Daiichi Sankyo weiten Forschungszusammenarbeit zur Entwicklung von Arzneimitteln in der Onkologie aus
Woburn, Massachusetts (ots/PRNewswire) – ArQule, Inc. und Daiichi Sankyo Co., Ltd. (TSE4568) gaben heute die Erweiterung ihrer Forschungs-, Entwicklungs- und Lizenzvereinbarung für die Entdeckung neuer Kinase-Inhibitoren im Bereich der Onkologie bekannt. Diese erweiterte Vereinbarung etabliert ein drittes Therapieziel, mit einer Option für ein viertes – im Bereich der Onkologie – und schliesst eine zweijährige Verlängerung [...]
Phase II Study Showed Switching ACS-PCI patients on maintenance clopidogrel/aspirin to prasugrel/aspirin reduced maximal platelet aggregation after one week
Indianapolis and Tokyo (ots/PRNewswire) – In a Phase II study, Acute Coronary Syndrome (ACS) patients on maintenance clopidogrel/aspirin therapy who were switched to prasugrel (Efient(R) – either 10 mg maintenance dose [MD] or 60 mg loading dose [LD] followed by 10 mg MD) plus aspirin demonstrated a statistically significant greater reduction in Maximal Platelet Aggregation [...]
DAIICHI SANKYO Announces Enrollment in the Two Largest Single Phase III Trials so far for the Prevention of Stroke in AF and for the Treatment of VTE is Proceeding as Planned
Stockholm (ots/PRNewswire) – DAIICHI SANKYO announced today that the ongoing trials ENGAGE AF-TIMI 48 (The Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation) and HOKUSAI VTE with their investigational factor Xa inhibitor edoxaban are enrolling in accordance to plan. The projected recruitment of ENGAGE AF-TIMI 48 and HOKUSAI VTE are 20,500 and 7,500 [...]
Edoxaban Demonstrates Superior Efficacy Compared With Enoxaparin Sodium in Preventing VTE After Total Knee Replacement
Tokyo, July 12, 2010 (ots/PRNewswire) – Daiichi Sankyo Company, Limited announced that its investigational once-daily oral, direct factor Xa inhibitor, edoxaban, was shown to be superior to enoxaparin in preventing venous thromboembolic (VTE) events in patients following total knee replacement (TKR), a type of major orthopedic surgery. Results from the Phase III STARS E-3 (Studying [...]
